Response Evaluation Criteria in Gastrointestinal and Abdominal Cancers: Which to Use and How to Measure-Reference-Cited by-同舟云学术

Response Evaluation Criteria in Gastrointestinal and Abdominal Cancers: Which to Use and How to Measure

Published:2024-05-01 Issue:5 Volume:44 Page:
ISSN:0271-5333
Container-title:RadioGraphics
language:en
Short-container-title:RadioGraphics

Author:

Castagnoli Francesca¹^ORCID,Mencel Justin¹,ap Dafydd Derfel¹,Gough Jessica¹,Drake Brent¹,Mcaddy Naami Charlotte¹,Withey Samuel Joseph¹^ORCID,Riddell Angela Mary¹^ORCID,Koh Dow-Mu¹,Shur Joshua David¹

Affiliation:

1. From the Departments of Radiology (F.C., D.a.D., N.C.M., S.J.W., A.M.R., D.M.K., J.D.S.), Oncology (J.M.), Radiotherapy (J.G.), and Nuclear Medicine (B.D.), Royal Marsden Hospital, Downs Road, Sutton SM2 5PT, UK; and Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK (F.C., D.M.K.).

Funder

NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research

Publisher

Radiological Society of North America (RSNA)

Link

http://pubs.rsna.org/doi/pdf/10.1148/rg.230047

Reference63 articles.

1. Global Burden of 5 Major Types of Gastrointestinal Cancer

2. Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using 18F-FDG PET in luminal HER2-negative breast cancer

3. The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis

4. HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison

5. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial